JP2025507571A5 - - Google Patents
Info
- Publication number
- JP2025507571A5 JP2025507571A5 JP2024548426A JP2024548426A JP2025507571A5 JP 2025507571 A5 JP2025507571 A5 JP 2025507571A5 JP 2024548426 A JP2024548426 A JP 2024548426A JP 2024548426 A JP2024548426 A JP 2024548426A JP 2025507571 A5 JP2025507571 A5 JP 2025507571A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical composition
- lnp
- cancer
- antigenic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311716P | 2022-02-18 | 2022-02-18 | |
| US63/311,716 | 2022-02-18 | ||
| US202263381460P | 2022-10-28 | 2022-10-28 | |
| US63/381,460 | 2022-10-28 | ||
| PCT/US2023/062844 WO2023159197A1 (en) | 2022-02-18 | 2023-02-17 | Mrnas encoding checkpoint cancer vaccines and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507571A JP2025507571A (ja) | 2025-03-21 |
| JP2025507571A5 true JP2025507571A5 (enExample) | 2026-02-26 |
Family
ID=85703979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548426A Pending JP2025507571A (ja) | 2022-02-18 | 2023-02-17 | チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250213664A1 (enExample) |
| EP (1) | EP4479085A1 (enExample) |
| JP (1) | JP2025507571A (enExample) |
| TW (1) | TW202345864A (enExample) |
| WO (1) | WO2023159197A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026008026A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Pd-l1 cancer vaccines and uses thereof |
| WO2026008017A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| DE21212055T1 (de) | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HRP20220156T1 (hr) * | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| HUE064857T2 (hu) * | 2016-03-04 | 2024-04-28 | Io Biotech Aps | Kombinációs terápia a rák ellen |
| RS63625B1 (sr) | 2016-05-18 | 2022-10-31 | Modernatx Inc | Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba |
| CA3042015A1 (en) * | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
-
2023
- 2023-02-17 EP EP23711903.7A patent/EP4479085A1/en active Pending
- 2023-02-17 US US18/839,326 patent/US20250213664A1/en active Pending
- 2023-02-17 JP JP2024548426A patent/JP2025507571A/ja active Pending
- 2023-02-17 TW TW112105879A patent/TW202345864A/zh unknown
- 2023-02-17 WO PCT/US2023/062844 patent/WO2023159197A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| BR112017005821B1 (pt) | Kit compreendendo lipossoma de dope/dotma/dotap e rna, método para a preparação de uma composição farmacêutica e método para quimicamente estabilizar uma dispersão lipossômica aquosa | |
| TW201408309A (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| Rizvi et al. | Immunotherapy for unresectable stage III non-small-cell lung cancer. | |
| CN111905099A (zh) | 用于改善存活蛋白疫苗在癌症治疗中的功效的方法 | |
| Katakami et al. | Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer | |
| EP4005591A1 (en) | Anti-neoplastic combined pharmaceutical composition and application thereof | |
| JP2022547298A5 (enExample) | ||
| JP2024520477A (ja) | ペプチドに基づくネオ抗原ワクチンの多成分化学組成物 | |
| JP2022512384A5 (enExample) | ||
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| CN115920019A (zh) | 一种治疗肺癌及其骨转移的mRNA疫苗及其制备方法与应用 | |
| WO2020131656A1 (en) | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | |
| WO2018101831A1 (en) | Pharmaceutical composition for use in the treatment of cancer | |
| JP2021536239A5 (enExample) | ||
| Zhang et al. | A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research | |
| US20250319172A1 (en) | Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof | |
| EP2966092A1 (en) | Novel peptide having 5 linked ctl epitopes | |
| JP2019532635A (ja) | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 | |
| JP7780824B2 (ja) | Ｈｅｒ２ワクチン組成物 | |
| US8796013B2 (en) | Pre-or post-exposure treatment for filovirus or arenavirus infection | |
| JP2016520073A (ja) | Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法 | |
| JP7062754B2 (ja) | ｈａＮＫセツキシマブ併用及び方法 | |
| JP2006502193A (ja) | 前立腺疾病を治療するためのヨクイニン油軟カプセル剤 | |
| JP2022512903A (ja) | Ａｄ－ＲＥＩＣ／Ｄｋｋ－３とチェックポイント阻害剤とを用いた胸部がんの治療のための併用療法 |